

## **CURRICULUM VITAE**

Edward Joseph Licitra MD, PhD  
18 Rue Cezanne  
Somerset, NJ 08873  
732-873-5273 (Home)  
email : [e\\_licitra@yahoo.com](mailto:e_licitra@yahoo.com)

OFFICE:  
Regional Cancer Care Associates LLC  
J2 Brier Hill Court  
East Brunswick, NJ 08816

Regional Cancer Care Associates LLC  
454 Elizabeth Avenue, Suite 240  
Somerset, NJ 08873  
Ph: 732-390-7750 Fax: 732-390-7725

### **EDUCATION**

<b>08/1996-05/2000 MD</b>	University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School Piscataway, New Jersey
<b>08/1991-08/1996 PhD</b>	Massachusetts Institute of Technology Cambridge, Massachusetts Biochemistry/Synthetic Organic Chemistry
<b>08/1986-05/1990 BA</b>	College of the Holy Cross, Worcester, Massachusetts Chemistry

### **POSTDOCTORAL TRAINING**

<b>7/2002-6/2005</b>	Fellowship – Medical Oncology UMDNJ-Robert Wood Johnson Medical School Piscataway, New Jersey Departments of Hematology and Oncology
<b>7/2001-6/2002</b>	Resident – Internal Medicine UMDNJ-Robert Wood Johnson Medical School Piscataway, New Jersey
<b>7/2000-6/2001</b>	Internship – Internal Medicine UMDNJ-Robert Wood Johnson Medical School Piscataway, New Jersey

**LICENSURE AND CERTIFICATION**

2001	Medical License, New Jersey	25MA07301300
2003	Diplomate: Internal Medicine	221931
2005	Diplomate: Medical Oncology	221931

**HOSPITAL APPOINTMENTS**

3/2006-Present	Attending Physician Robert Wood Johnson University Hospital, New Brunswick, NJ
4/2006-Present	Attending Physician St. Peter's University Hospital, New Brunswick, NJ

**PROFESSIONAL POSITIONS**

1/2012-Present	Chairman of the Board of Directors Regional Cancer Care Associates LLC
3/2006-Present	Private Practice Central Jersey Oncology Center, New Brunswick, NJ Medical Oncologist
7/2005-3/2006	Memorial Sloan Kettering Cancer Center New York, NY (Denville, NJ) Instructor-Department of Medicine
7/1990-7/1991	Wyeth-Ayerst Pharmaceuticals Princeton Junction, NJ Medicinal Chemist

**Edward J. Licitra, MD, PhD**

**RESEARCH EXPERIENCE**

**2003-Present**                      Participate in ECOG, NSABP, Biomedical and Pharmaceutical Phase II-III studies

**2003-2004**                      Cancer Institute of New Jersey  
Dean and Betty Gallo Prostate Cancer Institute  
Center for the Advancement of Biotechnology and Medicine

Generation of genetically engineered rat prostate cancer cells with a defined genetic background.  
Utilization of these cell lines to dissect pathways of apoptosis and drug sensitivity.  
Development of clinical trials for the treatment on prostate cancer.

**1996-1999**                      Cancer Institute of New Jersey

Investigation of novel chemotherapeutic/hormonal agent combinations and the development of clinical trials for the treatment of neoplastic disease.

**1991-1996**                      Massachusetts Institute of Technology

Development of a yeast three-hybrid system which allows for the rapid cloning of genes that encode for novel protein receptors of pharmacologically active small organic molecules.

Synthetic organic studies directed toward the total synthesis of taxol and taxol analogs.

Investigation of novel pharmacological agents for the treatment of neoplastic disease using both *in vitro* and *in vivo* models.

**1990-1991**                      Wyeth-Ayerst Pharmaceuticals

Design and synthesis of pharmacologically active analogs of the immunosuppressant rapamycin.

**1989-1990**                      College of the Holy Cross

Design and synthesis of novel local anesthetics.

**AWARDS AND HONORS**

Phi Beta Kappa  
Alpha Sigma Nu (Jesuit Honor Society)  
Joseph Cahill Prize in Chemistry (Holy Cross)  
Moore and Packard Predoctoral Fellow (MIT)  
National Cancer Institute Predoctoral Fellow (MIT)  
Alpha Omega Alpha (RWJMS, National Medical Honor Society)  
Robert Wood Johnson Medical School Research Award

## **Edward J. Licitra, MD, PhD**

Robert Wood Johnson Medical School Department of Internal Medicine Outstanding PGY2 Resident

2013-New Jersey Monthly Magazine: Top Docs / Oncology

2012-New Jersey Monthly Magazine: Top Docs / Oncology

### **PUBLICATIONS**

Licitra, E.J., Vyas, V., Nelson, K., Musanti, R., Beers, S., Thomas, C., Poplin, E., Smith, S., Lin, Y., Schaaf, L.J., Aisner, J., Gounder, M., Rajendra, R., Saleem, A., Toppmeyer, D., Rubin, E.H. Phase I Evaluation of Sequential Topoisomerase Targeting with Irinotecan/Cisplatin Followed by Etoposide in Patients with Advanced Malignancy *Clinical Cancer Research*; 9:1673-1679, 2003.

DiPaola, R.S., Zhang, H., Lambert, G.H., Meeker, R., Licitra, E.J., Rafi, M.M., Zhu, B.T., Spaulding, H., Goodin, S., Toledano, M.B., Hait, W.N., and Gallo, M.A. Clinical and biological activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. *New England Journal of Medicine*, 339:785-795,1998.

Lanni, J.S., Lowe, S.W., Licitra, E.J., Liu, J.O., and Jacks, T. Paclitaxel induces p53 independent apoptosis through an indirect mechanism. *Proceedings of the National Academy of Sciences*, 94:9679-9683,1997.

Licitra, E.J. and Liu, J.O. A three-hybrid system for detecting small ligand-protein receptor interactions. *Proceedings of the National Academy of Sciences*, 93:12817-12821,1996.

### **ABSTRACTS**

Licitra, E.J., Todd, M.B., and DiPaola R.S. Vinblastine or paclitaxel enhance mitoxantrone antitumor activity in a sequence dependent manner in association with bcl-2 phosphorylation. *American Society of Clinical Oncology 1998 Meeting Abstract #946*.

### **BOOK CHAPTERS**

Griffith, E.C., Licitra, E.J., and Liu, J.O. Yeast Three-Hybrid System for Detecting Ligand-Receptor Interactions. *Methods in Enzymology* 328:89-103 2000.

### **PATENTS**

Licitra, E.J. and Liu, J.O. A three-hybrid screening system for the detection of small ligand-protein receptor interactions. *United States Patent* 5,928,868.

Revised: 11/2014